Jane Street Group LLC Lowers Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Jane Street Group LLC lessened its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 46.9% during the third quarter, Holdings Channel.com reports. The firm owned 42,586 shares of the company’s stock after selling 37,601 shares during the quarter. Jane Street Group LLC’s holdings in EyePoint Pharmaceuticals were worth $340,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its holdings in EyePoint Pharmaceuticals by 59.4% in the 3rd quarter. Wellington Management Group LLP now owns 171,764 shares of the company’s stock valued at $1,372,000 after purchasing an additional 64,008 shares in the last quarter. Patient Square Capital LP purchased a new stake in EyePoint Pharmaceuticals in the 3rd quarter valued at approximately $10,882,000. Charles Schwab Investment Management Inc. boosted its holdings in EyePoint Pharmaceuticals by 5.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after purchasing an additional 7,967 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of EyePoint Pharmaceuticals during the 3rd quarter worth approximately $136,000. Finally, GSA Capital Partners LLP boosted its stake in shares of EyePoint Pharmaceuticals by 129.6% during the 3rd quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock worth $264,000 after acquiring an additional 18,616 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Price Performance

NASDAQ:EYPT opened at $9.11 on Thursday. The firm has a 50-day moving average of $8.96 and a two-hundred day moving average of $8.99. The stock has a market cap of $621.77 million, a P/E ratio of -4.56 and a beta of 1.49. EyePoint Pharmaceuticals, Inc. has a 1-year low of $6.90 and a 1-year high of $30.99.

Analyst Ratings Changes

Several equities research analysts have recently commented on EYPT shares. Citigroup started coverage on EyePoint Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $33.00 price target on the stock. Chardan Capital boosted their price target on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Robert W. Baird decreased their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research note on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.